33259-72-2

Basic information

• Product Name: 5,6-DIAMINO-2-PICOLINE,
• Synonyms: 2,3-Diamino-6-methylpyridine;6-Methyl-2,3-pyridinediamine;2,3-PyridinediaMine, 6-Methyl-
• CAS NO: 33259-72-2
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123
• EINECS: 1312995-182-4
• Mol File: 33259-72-2.mol
• Article Data: 19

Chemical Properties

• Melting Point: 69-70℃
• Boiling Point: 295℃
• Flash Point: 157℃
• Appearance: /
• Density: 1.190
• Vapor Pressure: 0.00161mmHg at 25°C
• Refractive Index: 1.4690 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.88±0.50(Predicted)
• CAS DataBase Reference: 5,6-DIAMINO-2-PICOLINE,(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DIAMINO-2-PICOLINE,(33259-72-2)
• EPA Substance Registry System: 5,6-DIAMINO-2-PICOLINE,(33259-72-2)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 33259-72-2(Hazardous Substances Data)

Usage

General Description

5,6-DIAMINO-2-PICOLINE, also known as 2-amino-5,6-pyridinediamine, is a chemical compound with the molecular formula C6H8N4. It is a derivative of picoline and is commonly used as an intermediate in the production of pharmaceuticals and agrochemicals. 5,6-DIAMINO-2-PICOLINE is a white to pale-yellow crystalline powder and is soluble in water and ethanol. It is primarily used in the synthesis of organic compounds, and its properties make it useful in the development of various industrial and commercial products. It is important to handle and store this compound with caution, as it can be harmful if ingested, inhaled, or comes into contact with skin.

InChI:InChI=1/C6H9N3/c1-4-2-3-5(7)6(8)9-4/h2-3H,7H2,1H3,(H2,8,9)/p+1

Upstream product

• 21901-29-1 6-amino-5-nitro-2-picoline 
• 1824-81-3 2-Amino-6-methylpyridine 
• 39745-40-9 2-chloro-6-methyl-3-aminopyridine 
• 19346-45-3 2-fluoro-3-nitro-6-methylpyridine 

Downstream Products

• 27582-24-7 5-methylpyridol[2,3-d]imidazole 
• 59352-86-2 6-methyl-2,3-diphenyl-pyrido[2,3-b]pyrazine 
• 144563-52-0 2-<2-Methoxy-4-(methylthio)phenyl>-5-methylimidazo-1H-<4,5-b>pyridin 
• 155629-96-2 6-methylpyrido<2,3-b>pyrazine 
• 129011-99-0 2-(4-Methoxy-phenyl)-5-methyl-1H-imidazo[4,5-b]pyridine 
• 129011-99-0 2-(4-methoxyphenyl)-5-methyl-3H-imidazo<4,5-b>pyridine 
• 88406-57-9 5-Methyl-2-phenyl-1H-imidazo[4,5-b]pyridine 
• 135145-97-0 5-Methyl-2-propyl-3H-imidazo[4,5-b]pyridine 
• 193533-15-2 (5-methyl-1H-imidazo[4,5-b]pyridin-2-ylmethyl)-carbamic acid benzyl ester 
• 220658-95-7 2-aminomethyl-5-methyl-1(H)-imidazo-4-pyridine 
• 193534-43-9 {4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-ylmethyl)-carbamoyl]-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid methyl ester 
• 155630-00-5 ethyl pyrazino<2,3-g>indolizine-2-carboxylate 
• 144563-54-2 (+/-)-2-<2-Methoxy-4-(methylsulfinyl)phenyl>-5-methylimidazo-1H-<4,5-b>pyridin 

Relevant articles and documents

Pyridone or pyrimidinone derivatives as well as preparation method and application thereof

The present invention relates to pyridone or pyrimidinone derivatives. The invention discloses a preparation method and application thereof in medicine. , The present invention relates to a pyridone or pyrimidinone derivative represented by general formula (I), a preparation method thereof and a pharmaceutically acceptable salt thereof and as a therapeutic agent, in particular as a coagulation factor XIa (FXIa) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as defined in the specification.

Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity

In the preceding manuscript [Moreau et al. 2018, 10.1021/acs.jmedchem.7b01691] we described a successful fragment-based lead discovery (FBLD) strategy for discovery of bacterial phosphopantetheine adenylyltransferase inhibitors (PPAT, CoaD). Following several rounds of optimization two promising lead compounds were identified: triazolopyrimidinone 3 and 4-azabenzimidazole 4. Here we disclose our efforts to further optimize these two leads for on-target potency and Gram-negative cellular activity. Enabled by a robust X-ray crystallography system, our structure-based inhibitor design approach delivered compounds with biochemical potencies 4-5 orders of magnitude greater than their respective fragment starting points. Additional optimization was guided by observations on bacterial permeability and physicochemical properties, which ultimately led to the identification of PPAT inhibitors with cellular activity against wild-type E. coli.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.